ALLO News and Press, Allogene Therapeutics Inc. From 03/23/22

Results Demonstrated Anti-BCMA CAR T Cells Derived from Healthy Donors Had Better Immune Fitness and Killing Activity Phase 1 AlloCAR T™ Trials Underway Evaluating ALLO-715 and ALLO-605 for the Treatment of Relapsed/Refractory Multiple Myeloma BCMA Program Clinical Update E...

French clinical-stage biotechnological company, Cellectis (CLLS +9.0%) is trading higher for the fourth consecutive session on Friday as the market reacts to the Fast Track designation granted by the U.S. Food and Drug Administration (FDA) for its partner Allogene Therapeutics (NASDAQ:ALLO). ...

ALLO-316 is an allogeneic CAR T therapy candidate targeting CD70, which Has Broad Potential Application Across a Variety of Solid Tumors and Hematologic Malignancies Phase 1 TRAVERSE Trial of ALLO-316 for the Treatment of Renal Cell Carcinoma (RCC) ongoing SOUTH SAN FRANCISCO, C...

On Wednesday, life sciences company, MaxCyte (NASDAQ:MXCT) announced the appointment of Dr. Cenk Sumen as its new Chief Scientific Officer. Prior to his appointment, Sumen served Stemson Therapeutics as the Chief Technology Officer, and before that, he has worked for companies including Therm...

Comprehensive Report Highlights Efforts to Advance Diversity, Equity and Inclusion, Sustainable Business Practices, and Corporate Governance SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology com...

The following slide deck was published by Allogene Therapeutics, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Allogene Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation

Allogene Therapeutics, Inc. (ALLO) Q4 2021 Earnings Conference Call February 23, 2022 05:00 PM ET Company Participants Christine Cassiano - Chief Communications Officer David Chang - President & Chief Executive Officer Rafael Amado - Executive Vice President, Research & Development &a...

Allogene Therapeutics press release (NASDAQ:ALLO): Q4 GAAP EPS of -$0.54 beats by $0.06. Revenue of $51K. The Company had $810 million in cash, cash equivalents, and investments as of December 31, 2021. Allogene expects full year GAAP Operating Expenses to be between $360 million and $390 mil...

AlloCAR T™ Studies Resumed and Currently Enrolling Patients Following Removal of Clinical Hold in January 2022 Phase 1 Data from the ALPHA Trials in Relapsed/Refractory (RR) Non-Hodgkin Lymphoma Presented at ASH 2021 Demonstrated Potential for an AlloCAR T Product to be a Safe ...

AAN, ACA, OTCPK:ACLLF, AEM, AEVA, AGI, AHT, ALLO, ALR, AMED, ANSS, ARNA, AZUL, BAND, BBDC, BBWI, BCSF, BHP, BIRD, BKNG, BMA, BMRN, CCRN, CDEV, CHDN, CHK, CLOV, CMLS, CPE, CSV, CTRA, CW, DHC, DK, DKL, EBAY, EFC, OTCPK:EIFZF, EVH, EXR, FBRT, FIVN, FIX, FLGT, FLS, FNF, FRG, FTI, FUBO, GBT, GH, G...